MedTrace Logo

Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy

NCT05949333 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-02-23

No results posted yet for this study

Summary

Patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first round are randomly assigned to either the control or experimental arm. Patients in the control arm continue pegfilgrastim injection on day 1 while patients in the experimental arm will receive pegfilgrastim injection on day 3 to see if changing the pegfilgrastim administration date from day 1 to day 3 starting from the second round of chemotherapy could reduce the incidence of neutropenia

Conditions

  • Breast Neoplasms

Interventions

DRUG

Eflapegrastim

long-acting granulocyte-colony stimulating factor

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    collaborator INDUSTRY

  • Eunseong Medical Foundation Good GANG-AN HOSPITAL

    lead OTHER

Principal Investigators

  • Chang Wan Jeon, Ph.D · Surgical Oncologist

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-07
Primary Completion
2025-01-31
Completion
2025-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05949333 on ClinicalTrials.gov